In Pfizer-Seagen Review, FTC has Chance to Set New Pharma Precedent
March 14, 2023
Jonathan Gardner
BioPharma Dive
Axinn partner Jeny Maier was quoted in the BioPharma Dive article, "In Pfizer-Seagen Review, FTC has Chance to Set New Pharma Precedent."
Click here to access the article.